Ligand Pharmaceuticals received a rating increase and price target raise from Bank of America on August 5, while the company also listed its stock on Nasdaq.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ligand Pharmaceuticals received a rating increase and price target raise from Bank of America on August 5, while the company also listed its stock on Nasdaq.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
Nothing else this week.
-
Bank of America
American multinational banking and financial services corporation
Related events
- Ligand Pharmaceuticals filed a transaction with the SEC, while Royal Bank of Canada lifted its target price, and the stock is listed on Nasdaq.
- Amphenol received multiple analyst upgrades and target price increases from firms including Citigroup, Bank of America, and Jefferies Financial Group on July 9, 2026.
- Bank of America, Citigroup, and Royal Bank of Canada issued rating upgrades and price target increases for International Paper.
- Multiple major banks, including Citigroup, UBS, Bank of America, and Barclays, have issued updated price targets and ratings.
- Bank of America raised its price target for Walmart, citing gains in market share and AI businesses.